for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Clearside Biomedical Inc

CLSD.O

Latest Trade

4.16USD

Change

1.14(+37.75%)

Volume

90,824,682

Today's Range

3.62

 - 

4.80

52 Week Range

1.25

 - 

4.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.02
Open
4.00
Volume
90,824,682
3M AVG Volume
4.71
Today's High
4.80
Today's Low
3.62
52 Week High
4.80
52 Week Low
1.25
Shares Out (MIL)
57.58
Market Cap (MIL)
173.31
Forward P/E
-14.47
Dividend (Yield %)
--

Next Event

Clearside Biomedical Inc at JMP Securities Life Sciences Virtual Conference

Latest Developments

More

Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For Xiper (Triamcinolone Acetonide Suprachoroidal Injectable Suspension)

Clearside Biomedical Reports Q1 Loss Per Share Of $0.13

Clearside Biomedical Announces Fourth Quarter And Full Year 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Clearside Biomedical Inc

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting three components of the eye: the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision; the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment, and the sclera, which is the outer protective layer of the eye. The Company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide formulated for administration via suprachoroidal injection.

Industry

Biotechnology & Drugs

Contact Info

900 N Point Pkwy Ste 200

ALPHARETTA, GA

30005-8995

United States

+1.678.2703631

http://clearsidebio.com/

Executive Leadership

Christy L. Shaffer

Independent Chairman of the Board

George Lasezkay

President, Chief Executive Officer, Director

Charles A. Deignan

Chief Financial Officer

Richard J. Croarkin

Independent Director

Jeffrey L. Edwards

Independent Director

Key Stats

2.20 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-2.690

2019

-0.810

2020

-0.390

2021(E)

-0.208
Price To Earnings (TTM)
--
Price To Sales (TTM)
45.24
Price To Book (MRQ)
10.20
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-157.31
Return on Equity (TTM)
-85.69

Latest News

Latest News

BRIEF-Clearside Biomedical Files For Common Stock Offering Of Upto $50 Mln

* CLEARSIDE BIOMEDICAL INC FILES FOR COMMON STOCK OFFERING OF UPTO $50.0 MILLION - SEC FILING Source text: (https://bit.ly/3cTYqdq) Further company coverage:

BRIEF-Clearside Biomedical Inc Files For Mixed Shelf Of Upto $250 Million - SEC Filing

* CLEARSIDE BIOMEDICAL INC FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING Source text for Eikon: https://bit.ly/2Wdfghg Further company coverage:

BRIEF-Clearside Biomedical Revises NDA Resubmission Timeline And XIPERE Commercial Deal With Bausch Health

* CLEARSIDE BIOMEDICAL REVISES NDA RESUBMISSION TIMELINE AND XIPERE™ COMMERCIAL PARTNERSHIP WITH BAUSCH HEALTH

BRIEF-Clearside Biomedical Appoints Nancy J. Hutson To Board Of Directors

* CLEARSIDE BIOMEDICAL APPOINTS NANCY J. HUTSON, PH.D. TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Clearside Biomedical Posts Quarterly Loss Per Share Of $0.07

* CLEARSIDE BIOMEDICAL ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Clearside Biomedical Appoints Dr. George Lasezkay As President And Chief Executive Officer

* CLEARSIDE BIOMEDICAL APPOINTS DR. GEORGE LASEZKAY AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

BRIEF-Clearside Biomedical Announces License Agreement With Arctic Vision For Xipere™ In Greater China And South Korea

* CLEARSIDE BIOMEDICAL ANNOUNCES LICENSE AGREEMENT WITH ARCTIC VISION FOR XIPERE™ (TRIAMCINOLONE ACETONIDE SUPRACHOROIDAL INJECTABLE SUSPENSION) IN GREATER CHINA AND SOUTH KOREA

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up